UnitedHealth Group (UNH) — Earnings Preview Memo
Key Points Table
| Focus Area | Details & What to Watch |
|---|---|
| 2026 Guidance | Raised FY26 adj. EPS guidance to $19.50–$20 (+13% to +15% YoY); prior guide was >$17.75. |
| Medicare Advantage | Outperforming initial 2026 margin targets; now expect MA margins above 3% for FY26, with enrollment decline revised to -1.1M (better than prior -1.3M to -1.4M). Watch for continued margin expansion and trend durability. |
| Commercial Segment | Commercial cost trends remain stubbornly high (>11%), with IDR process adding ~100 bps of cost. Margin recovery delayed beyond 2027. Monitor for any signs of trend moderation or further pressure. |
| Medicaid | Margins tracking at the better end of guided range (-1.1% to -1.7%), with rates and trends as expected. 2026 is a trough year; look for commentary on rate catch-up and cost initiatives for 2027. |
| OptumHealth | Strong margin and profit outperformance in 1H26, driven by clinical and operating execution. Margin expansion expected to continue into 2027/28. Watch for sustainability of improvements and progress on external payer contracting. |
| AI & Cost Initiatives | $1.5B+ AI investment in 2026; management expects compounding SG&A savings and operational leverage, especially in OptumInsight and enterprise-wide. |
| Capital Returns | Buybacks accelerated: $5B+ planned for FY26 (vs. $2.5B initial), dividend raised. Debt-to-capital target of 40% by year-end. |
| Stars & Regulatory | Stars volatility remains; management focused on operational levers and advocating for value-based care as a core to future Stars methodology. |
Summary and Conclusions
- UNH enters Q3 2026 earnings with strong momentum: FY26 adjusted EPS guidance was raised to $19.50–$20 (+13% to +15% YoY), reflecting broad-based outperformance, especially in Medicare Advantage and OptumHealth.
- Medicare Advantage is the key positive swing factor: Margin performance is running above plan, with full-year MA margins now expected above 3%. Enrollment attrition is less severe than initially feared. Benefit design, network curation, and care management are driving results.
- Commercial remains the main drag: Cost trends are running above 11%, with the IDR process under the No Surprises Act adding incremental pressure. Margin recovery is now a multi-year journey, with full normalization not expected until after 2027.
- Medicaid is at a trough, but stable: Margins are tracking at the better end of the guided loss range, with both rates and trends as expected. Management is confident in a return to breakeven/profitability in 2027, contingent on continued rate catch-up and cost actions.
- OptumHealth turnaround is ahead of schedule: Margin and profit outperformance in 1H26 is attributed to clinical and operational execution, not just favorable MA underwriting. Management expects further margin expansion in 2027/28, with most loss contracts addressed for 2027.
- AI and cost initiatives are a major focus: Over $1.5B invested in AI in 2026, with management expecting compounding SG&A savings and operational leverage, especially in OptumInsight and across the enterprise.
- Capital returns are accelerating: Buybacks have been increased to at least $5B for FY26, and the dividend was raised. Debt-to-capital is on track for 40% by year-end.
- Regulatory and Stars program remain wildcards: Management is focused on operational levers for Stars and is advocating for value-based care to be central to future program design.
Forward Consensus and Guidance vs. Prior Year
FY2026 Guidance vs. FY2025 Actuals
| Metric | FY2025 Actual | FY2026 Guidance (as of Q2) | YoY Change | Notes |
|---|---|---|---|---|
| Revenue ($M) | $447,990 | $447,083 | -0.2% | Flat revenue, reflects portfolio actions and membership mix shift |
| Adj. EPS ($) | $16.35 | $19.50–$20 | +19% to +22% | Raised from initial >$17.75; strong margin recovery in MA and OptumHealth |
| Net Income ($M) | $14,893 | $17,988 (consensus) | +21% | Consensus estimate |
| EBITDA ($M) | $26,196 | $29,540 (consensus) | +13% | Consensus estimate |
| Medical Care Ratio (%) | 89.1 | 88.1 ± 25 bps | -100 bps | Lower MCR driven by MA and OptumHealth improvement |
| Operating Cost Ratio (%) | 13.3 | High end of 12.8% ± 50 bps | Higher due to AI, people, community investments | |
| Buybacks ($B) | ≥$5 | Up from $2.5B initial guide | ||
| Dividend ($/share) | $9.28 (annualized) | Increased in Q2 |
Quarterly Trend — Most Recent Quarters
| Quarter | Revenue ($M) | Gross Margin (%) | EBITDA ($M) | Net Income ($M) | EPS ($) | Notes |
|---|---|---|---|---|---|---|
| Q2 2026 | 110,862 | 19.2 | 7,444 | 4,457 | 4.63 | Strong MA and OptumHealth; commercial pressured |
| Q1 2026 | 109,652 | 21.5 | 9,503 | 6,084 | 6.28 | Seasonally strong; high buyback activity |
| Q4 2025 | 113,730 | 16.5 | 4,414 | 1,928 | 1.73 | Includes restructuring charges |
| Q3 2025 | 113,057 | 17.7 | 5,175 | 2,496 | 2.40 |
Segment Highlights and KPIs
Medicare Advantage
- 2026 MA margins now expected above 3% (prior: ~2.5%).
- Enrollment attrition revised to -1.1M (better than prior -1.3M to -1.4M).
- Medical cost trend for 2026 coming in below initial 10% estimate; core utilization remains elevated but benefit design/network actions are working.
- 2027 bids positioned for further margin stability; management expects to remain in upper half of 2–4% long-term margin range.
Commercial
- Cost trend running modestly above 11%; IDR process adds ~100 bps of cost.
- Margin recovery delayed beyond 2027; management remains confident in eventual return to 7%+ margins, but timeline extended.
- Exchange business performing better than expected, but profits rebated to customers in 2026.
Medicaid
- Margins tracking at -1.1% (better end of -1.1% to -1.7% range).
- Rates and trends as expected; 6–7% blended rate increases achieved.
- 2026 is a trough year; management confident in return to breakeven/profitability in 2027, contingent on continued rate catch-up and cost actions.
OptumHealth
- Strong margin and profit outperformance in 1H26, driven by clinical and operating execution.
- Majority of loss contracts addressed for 2027; further margin expansion expected in 2027/28.
- Fee-for-service businesses improving, but still a turnaround focus.
OptumInsight
- Margins tracking at 18–22%, expected to finish 2026 at top end.
- Heavy AI investment year; new product launches (Optum Real, Crimson AI) gaining traction.
- 2027/28 expected to see compounding margin and revenue benefits from AI commercialization.
What to Watch Next Earnings
| Factor | Why It Matters / What to Watch |
|---|---|
| MA Margin Durability | Is outperformance in 1H26 sustainable? Will margins remain above 3% for FY26 and set up for upper half of 2–4% range in 2027? |
| Commercial Trend & Margins | Any sign of cost trend moderation? Progress on pricing for IDR impact? Updated timeline for margin normalization. |
| Medicaid Margin Inflection | Confirmation of trough in 2026; early signals of rate catch-up and cost actions for 2027. |
| OptumHealth Margin Expansion | Continued execution on clinical/operating levers; update on external payer contracting and network optimization. |
| AI-Driven SG&A Leverage | Quantification of realized and expected cost savings; impact on segment margins and OCR. |
| Capital Deployment | Pace of buybacks, dividend growth, and M&A pipeline. |
| Stars & Regulatory | Early read on 2027 Stars positioning; updates on regulatory/legislative environment (IDR, PBM, Stars). |
| Fee-for-Service Turnaround | Progress on profitability and operational improvement in FFS practices. |
How Did They Report Last Year? Are They Coming Off a Tough Comparable?
- FY2025 was a transition year with significant headwinds:
- Adjusted EPS: $16.35 (slightly ahead of expectations, but included $1.6B net-of-tax charge).
- Revenue: $447,990M (+12% YoY).
- Medical Care Ratio: 89.1% (high, reflecting elevated trends).
- Operating Cost Ratio: 13.3%.
- Major restructuring and portfolio actions taken in Q4 2025.
- Commercial and Medicaid segments underperformed; OptumHealth margins were at trough levels.
- Guidance for 2026 was for >$17.75 adj. EPS (+8.6% YoY), since raised twice.
- 2026 is a much easier comparable for Medicare and OptumHealth, but Commercial remains tough:
- MA margins and OptumHealth profitability are rebounding off a low base.
- Commercial faces a tougher comp due to persistent cost trend and IDR impact.
- Medicaid is at a trough, setting up for improvement in 2027.
Management Commentary — Recent Tone
- On MA and OptumHealth: "We really needed to make some tough decisions around the durability of the products we had, coupled with what we thought were sustainable margins over time... all trends are pointing in the right direction."
- On Commercial: "The sticky nature of the persistent and elevated trend is extending the time frame for full margin recovery past 2027... We remain on a multiyear journey."
- On Medicaid: "Both items are at expectations... this will be a trough year on Medicaid margins and then moving back to breakeven or profitability going into next year."
- On AI and Cost: "We're in a very unique world where AI becomes an incredibly positive catalyst to remove a lot of administrative inefficiencies... we're talking about billions that we plan to take out of the system."
- On Capital Returns: "We would expect to continue to raise our dividend. We would expect to deploy buyback at a much more aggressive pace. And we would expect to be reengaged in the acquisition space as we have historically been, albeit a lot more focused on what we think are the big growth drivers over time."
Summary Table — FY2026 Guidance vs. FY2025 Actuals
| Metric | FY2025 Actual | FY2026 Guidance (Q2) | YoY Change |
|---|---|---|---|
| Revenue ($M) | $447,990 | $447,083 | -0.2% |
| Adj. EPS ($) | $16.35 | $19.50–$20 | +19% to +22% |
| Net Income ($M) | $14,893 | $17,988 (consensus) | +21% |
| EBITDA ($M) | $26,196 | $29,540 (consensus) | +13% |
| Medical Care Ratio (%) | 89.1 | 88.1 ± 25 bps | -100 bps |
| Operating Cost Ratio (%) | 13.3 | High end of 12.8% ± 50 bps | |
| Buybacks ($B) | ≥$5 | ||
| Dividend ($/share) | $9.28 (annualized) |
Conclusion
UNH is entering its next earnings report with strong momentum, especially in Medicare Advantage and OptumHealth, and has raised FY26 guidance twice YTD. The company is coming off a transition year (2025) with easier comps in MA and OptumHealth, but Commercial remains challenged by persistent cost trend and regulatory headwinds. Key factors to watch are the durability of MA and OptumHealth margin outperformance, progress on commercial margin recovery, Medicaid inflection, realization of AI-driven cost savings, and capital deployment pace.
